Your browser doesn't support javascript.
loading
Calcium channel blockers may reduce the development of long COVID in females.
Ozawa, Takuya; Kimura, Ryusei; Terai, Hideki; Takemura, Ryo; Namkoong, Ho; Kondo, Masahiro; Fukuda, Keitaro; Yagi, Kazuma; Asakura, Takanori; Masaki, Katsunori; Chubachi, Shotaro; Miyata, Jun; Ohgino, Keiko; Kawada, Ichiro; Kagyo, Junko; Odani, Toshio; Kuwahara, Naota; Nakachi, Ichiro; Ishii, Makoto; Sato, Yasunori; Fukunaga, Koichi.
Affiliation
  • Ozawa T; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Kimura R; Pulmonary Division, Department Internal Medicine, Saiseikai Utsunomiya Hospital, Tochigi, Japan.
  • Terai H; Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.
  • Takemura R; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan. hidekit926@gmail.com.
  • Namkoong H; Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan. hidekit926@gmail.com.
  • Kondo M; Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan. rtakemura@keio.jp.
  • Fukuda K; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Yagi K; Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
  • Asakura T; Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.
  • Masaki K; Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.
  • Chubachi S; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Miyata J; Department of Internal Medicine, Keiyu Hospital, Yokohama, Kanagawa, Japan.
  • Ohgino K; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Kawada I; Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
  • Kagyo J; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Odani T; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Kuwahara N; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Nakachi I; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Ishii M; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Sato Y; Research Centers and Institutes, Health Center, Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Fukunaga K; Department of Internal Medicine, Keiyu Hospital, Yokohama, Kanagawa, Japan.
Hypertens Res ; 47(4): 934-943, 2024 Apr.
Article in En | MEDLINE | ID: mdl-37978232
With the rising numbers of patients infected with severe acute respiratory syndrome coronavirus 2, long coronavirus disease 2019 (COVID-19)-a sequelae of COVID-19-has become a major problem. Different sexes and age groups develop different long COVID symptoms, and the risk factors for long COVID remain unclear. Therefore, we performed subgroup analyses of patients with COVID-19, classifying them into different groups. In this multicenter cohort study, using an original questionnaire, we examined patients (≥18 years old) diagnosed with COVID-19 from November 2020 to March 2022 and hospitalized at participating medical facilities. In total, 1066 patients were registered (361 female, 620 male). Hypertension was the most common comorbidity (n = 344; 32.5%). Females with hypertension were significantly less likely to develop long COVID symptoms than those without hypertension (odds ratio [OR] 0.51, 95% confidence interval [CI] 0.27-0.98; p = 0.043). In females, Ca channel blocker administration, rather than having hypertension, was significantly associated with reductions in the frequency of alopecia (OR 0.14, 95% CI 0.03-0.67, p = 0.015), memory impairment (OR 0.14, 95% CI 0.02-0.82, p = 0.029), sleeping disorders (OR 0.17, 95% CI 0.04-0.67, p = 0.012), tinnitus (OR 0.23, 95% CI 0.05-0.98, p = 0.047), sputum (OR 0.31, 95% CI 0.10-0.92, p = 0.035), and fever (OR 0.33, 95% CI 0.12-0.93, p = 0.036). Several long COVID symptoms, including alopecia, were significantly negatively associated with Ca channel-blocker administration in female patients with long COVID. Calcium channel blockers may reduce the development of long COVID in females.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 / Hypertension Limits: Adolescent / Female / Humans / Male Language: En Journal: Hypertens Res Journal subject: ANGIOLOGIA Year: 2024 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 / Hypertension Limits: Adolescent / Female / Humans / Male Language: En Journal: Hypertens Res Journal subject: ANGIOLOGIA Year: 2024 Document type: Article Affiliation country: Country of publication: